Publication

Electrophysiological properties of isradipine (PN200-110) in humans

van Wijk, L. M., van den Toren, W. E., van Gelder, I., Crijns, H. J., Ruegg, P. & Lie, K. I., Sep-1989, In : Journal of Cardiovascular Pharmacology. 14, 3, p. 492-495 4 p.

Research output: Contribution to journalArticleAcademicpeer-review

APA

van Wijk, L. M., van den Toren, W. E., van Gelder, I., Crijns, H. J., Ruegg, P., & Lie, K. I. (1989). Electrophysiological properties of isradipine (PN200-110) in humans. Journal of Cardiovascular Pharmacology, 14(3), 492-495. https://doi.org/10.1097/00005344-198909000-00020

Author

van Wijk, L.M ; van den Toren, W.E ; van Gelder, I ; Crijns, H.J ; Ruegg, P ; Lie, K.I. / Electrophysiological properties of isradipine (PN200-110) in humans. In: Journal of Cardiovascular Pharmacology. 1989 ; Vol. 14, No. 3. pp. 492-495.

Harvard

van Wijk, LM, van den Toren, WE, van Gelder, I, Crijns, HJ, Ruegg, P & Lie, KI 1989, 'Electrophysiological properties of isradipine (PN200-110) in humans', Journal of Cardiovascular Pharmacology, vol. 14, no. 3, pp. 492-495. https://doi.org/10.1097/00005344-198909000-00020

Standard

Electrophysiological properties of isradipine (PN200-110) in humans. / van Wijk, L.M; van den Toren, W.E; van Gelder, I; Crijns, H.J; Ruegg, P; Lie, K.I.

In: Journal of Cardiovascular Pharmacology, Vol. 14, No. 3, 09.1989, p. 492-495.

Research output: Contribution to journalArticleAcademicpeer-review

Vancouver

van Wijk LM, van den Toren WE, van Gelder I, Crijns HJ, Ruegg P, Lie KI. Electrophysiological properties of isradipine (PN200-110) in humans. Journal of Cardiovascular Pharmacology. 1989 Sep;14(3):492-495. https://doi.org/10.1097/00005344-198909000-00020


BibTeX

@article{13c59156fc9b4804b9a1fbb4e4c26265,
title = "Electrophysiological properties of isradipine (PN200-110) in humans",
abstract = "Isradipine (PN 200-110) is a new dihydropyridine calcium-entry blocker with powerful vasodilating properties. Therapeutic concentrations do not affect myocardial contractility. However, in vitro studies have demonstrated at higher concentrations negative chronotropic action with only minor dromotropic influence. For this reason we studied the effect of intravenous isradipine (0.3 microgram/kg/min during 30 min) on sinus node and atrioventricular (AV) nodal function in 25 patients. Nine of these patients had normal sinus node function (group I), nine patients were treated with a beta blocker (group II), and seven patients had a sick sinus syndrome (group III). Mean supine arterial blood pressure decreased in all groups; however, in group I not significantly. Spontaneous sinus cycle length decreased significantly in all groups. In none of the patients effective refractory periods of atrium or ventricle were depressed. QRS duration was not significantly affected in any of the groups. There was only a slight, but significant, prolongation of the QTc of maximal 4% (except in group III). We concluded that isradipine has no depressant effect on sinus and AV nodal function in humans, not even in the presence of beta blockade or impaired sinus node function",
author = "{van Wijk}, L.M and {van den Toren}, W.E and {van Gelder}, I and H.J Crijns and P Ruegg and K.I Lie",
year = "1989",
month = sep,
doi = "10.1097/00005344-198909000-00020",
language = "English",
volume = "14",
pages = "492--495",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
number = "3",

}

RIS

TY - JOUR

T1 - Electrophysiological properties of isradipine (PN200-110) in humans

AU - van Wijk, L.M

AU - van den Toren, W.E

AU - van Gelder, I

AU - Crijns, H.J

AU - Ruegg, P

AU - Lie, K.I

PY - 1989/9

Y1 - 1989/9

N2 - Isradipine (PN 200-110) is a new dihydropyridine calcium-entry blocker with powerful vasodilating properties. Therapeutic concentrations do not affect myocardial contractility. However, in vitro studies have demonstrated at higher concentrations negative chronotropic action with only minor dromotropic influence. For this reason we studied the effect of intravenous isradipine (0.3 microgram/kg/min during 30 min) on sinus node and atrioventricular (AV) nodal function in 25 patients. Nine of these patients had normal sinus node function (group I), nine patients were treated with a beta blocker (group II), and seven patients had a sick sinus syndrome (group III). Mean supine arterial blood pressure decreased in all groups; however, in group I not significantly. Spontaneous sinus cycle length decreased significantly in all groups. In none of the patients effective refractory periods of atrium or ventricle were depressed. QRS duration was not significantly affected in any of the groups. There was only a slight, but significant, prolongation of the QTc of maximal 4% (except in group III). We concluded that isradipine has no depressant effect on sinus and AV nodal function in humans, not even in the presence of beta blockade or impaired sinus node function

AB - Isradipine (PN 200-110) is a new dihydropyridine calcium-entry blocker with powerful vasodilating properties. Therapeutic concentrations do not affect myocardial contractility. However, in vitro studies have demonstrated at higher concentrations negative chronotropic action with only minor dromotropic influence. For this reason we studied the effect of intravenous isradipine (0.3 microgram/kg/min during 30 min) on sinus node and atrioventricular (AV) nodal function in 25 patients. Nine of these patients had normal sinus node function (group I), nine patients were treated with a beta blocker (group II), and seven patients had a sick sinus syndrome (group III). Mean supine arterial blood pressure decreased in all groups; however, in group I not significantly. Spontaneous sinus cycle length decreased significantly in all groups. In none of the patients effective refractory periods of atrium or ventricle were depressed. QRS duration was not significantly affected in any of the groups. There was only a slight, but significant, prolongation of the QTc of maximal 4% (except in group III). We concluded that isradipine has no depressant effect on sinus and AV nodal function in humans, not even in the presence of beta blockade or impaired sinus node function

U2 - 10.1097/00005344-198909000-00020

DO - 10.1097/00005344-198909000-00020

M3 - Article

VL - 14

SP - 492

EP - 495

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 3

ER -

ID: 6237298